Erenzo Tablet 50 mg contains Roxadustat, a cutting-edge oral medication used for the treatment of anemia associated with chronic kidney disease (CKD). Roxadustat belongs to the class of hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs), which work by stimulating the body’s natural production of erythropoietin and improving iron metabolism. This dual action helps increase hemoglobin levels, alleviate symptoms of anemia, and enhance the overall quality of life in patients with CKD.

Anemia is a frequent complication in CKD, caused mainly by decreased erythropoietin production in the kidneys. Patients often experience fatigue, shortness of breath, reduced physical performance, and diminished quality of life. Erenzo Tablet 50 mg provides an effective oral treatment option, helping restore hemoglobin levels and reduce the need for blood transfusions, while avoiding the inconvenience of injectable therapies.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Key Features and Benefits

Active Ingredient:

• Roxadustat 50 mg per tablet

Effective Anemia Management:

• Stimulates endogenous erythropoietin production

• Enhances iron absorption and utilization

• Increases hemoglobin levels and oxygen delivery to tissues

Convenient Oral Therapy:

• Suitable for both dialysis and non-dialysis CKD patients

• Eliminates the need for frequent injections

• Supports better patient adherence and long-term management

Improved Quality of Life:

• Reduces fatigue, weakness, and shortness of breath

• Supports physical activity and daily functioning

• May decrease the need for allogeneic blood transfusions

How It Works

Roxadustat is a hypoxia-inducible factor (HIF) stabilizer that mimics the body’s natural response to low oxygen levels. By stabilizing HIF, Roxadustat promotes the production of erythropoietin in the kidneys and liver, which stimulates red blood cell formation in the bone marrow.

In addition to increasing erythropoietin production, Roxadustat regulates hepcidin levels, improving iron absorption from the gut and mobilizing stored iron. This ensures efficient hemoglobin synthesis and addresses both the erythropoietin deficiency and iron utilization issues commonly seen in CKD-related anemia.

Indications

Erenzo Tablet 50 mg is indicated for:

• Treatment of anemia in adult patients with chronic kidney disease, including those undergoing dialysis

• Management of anemia in non-dialysis CKD patients

• Patients requiring an oral alternative to injectable erythropoiesis-stimulating agents (ESAs)

Dosage and Administration

• Administer the tablet orally as prescribed by a healthcare professional.

• Usually taken three times per week or according to individualized dosing requirements.

• Swallow the tablet with water; it may be taken with or without food.

• Regular monitoring of hemoglobin, iron levels, and other relevant parameters is necessary to ensure safety and efficacy.

Do not adjust the dose or discontinue therapy without medical guidance.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Precautions and Safety Information

• Inform your doctor if you have a history of cardiovascular disease, hypertension, liver disease, or thromboembolic disorders.

• Common side effects may include headache, nausea, diarrhea, and high blood pressure.

• Serious adverse events, though rare, may include thrombosis, heart failure, myocardial infarction, or severe hypertension. Seek immediate medical attention if severe symptoms occur.

• Use caution in patients with a history of stroke or significant cardiovascular risk factors.

Storage Instructions

• Store in a cool, dry place below 30°C.

• Protect from light, moisture, and heat.

• Keep out of reach of children.

Erenzo Tablet 50 mg offers a modern, convenient oral therapy for managing anemia in CKD patients. Its dual mechanism of stimulating erythropoietin production and enhancing iron utilization effectively restores hemoglobin levels, reduces fatigue, and improves patient well-being, providing a safe and practical alternative to injectable therapies.